Pharmamar company information, Employees & Contact Information

PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer Yahoo Finance

Jazz, PharmaMar's Zepzelca cleared in US for first-line maintenance of ES-SCLC with Tecentriq FirstWord Pharma

Marine Pharmaceutical Market Size to Hit USD 10.26 Billion by 2034 Precedence Research

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study ScienceDirect.com

PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer PR Newswire

PharmaMar gets $10 million milestone from Janssen for Yondelis | Pharmaceutical | The Pharmaletter The Pharma Letter

CNIO and PharmaMar carry out drug testing project for breast cancer micrometastases Centro Nacional de Investigaciones Oncológicas - CNIO

PharmaMar shares soar after drug study suggests efficacy against Omicron Reuters

Sylentis’ siRNA Therapy Fails to Improve Symptoms of Dry Eye Disease Due to Sjögren’s Syndrome CGTLive®

Outline Nature

PharmaMar FY 2024 slides: Revenue up 11%, net profit soars amid clinical advances Investing.com

PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer PR Newswire UK

ASCO 25: Jazz, PharmaMar reveal SCLC survival data pharmaphorum

PharmaMar's Cancer Drug Inspired by Sea Animal Gets FDA Green Light Labiotech.eu

PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. PR Newswire

ASCO25: Jazz, PharmaMar drug combo delivers survival boost in SCLC FirstWord Pharma

Spain's PharmaMar posts 58% drop in 9-mth profit despite higher revenues Reuters

PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period PR Newswire

FDA grants priority review for Jazz, PharmaMar's lurbinectedin in second-line SCLC FirstWord Pharma

PharmaMar’s MM drug gets another chance to win approval in Europe FirstWord Pharma

Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer PR Newswire

EMA Poised To Decide On Fate Of Lilly’s Kisunla And PharmaMar’s Aplidin In EU Citeline News & Insights

PharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer PR Newswire UK

FDA approves Zepzelca (Pharma Mar) + Tecentriq (Roche) combination therapy for treating lung cancer The Corner .eu

EC ordered to pay cost of PharmaMar vs EMA case European Biotechnology Magazine

WCLC: Jazz charts new path for small cell lung cancer drug Zepzelca after late-stage flop Fierce Pharma

PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting PR Newswire

Jazz preps first solid tumor launch with Zepzelca's small cell lung cancer nod Fierce Pharma

Pharmamar receives $50 million from Jazz Pharma for approval of Zepzelca + Tecentriq combo treatment for small cell lung cancer The Corner .eu

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedin pharmaphorum

PharmaMar set to seek accelerated FDA approval of lurbinectedin in small-cell lung cancer FirstWord Pharma

EMA-Gate: PharmaMar wins suit against EMA European Biotechnology Magazine

Aplidium albicans (IMAGE) EurekAlert!

Chugai ends licence for PharmaMar’s lurbinectedin European Biotechnology Magazine

Zeltia restructures and rebrands as PharmaMar, Edison increases valuation | Pharmaceutical | The Pharmaletter The Pharma Letter

IRB and PharmaMar invent a method to reproduce marine substances of pharmacological interest Institute for Research in Biomedicine | IRB Barcelona

Pharmamar Runs Into Rival For Its Corona And Flu Test ABC Money